by GMFH Editing Team
This clinically-oriented summary of gut microbiota research was developed by members of the Gut Microbiota and Health section of the European Society of Neurogastroenterology & Motility (ESNM), and was approved by the Board of Directors of the Section and by the Steering Committee of ESNM.
by Heather Galipeau
In a recently published paper in Nature Medicine, a group led by Harry Sokol at INRA studied how host genes affect the composition and function of the gut microbiota, and in turn, the production of metabolites and intestinal inflammation.
by Paul Enck
A recent study, led by Mr. Michael Shahani from Nebraska Cultures in Walnut Creek (California, USA), has found that a specific strain of Lactobacillus acidophilus may provide symptom benefits after 4 weeks of use, compared with a placebo, among individuals with lactose intolerance.
by Heather Galipeau
Gluten is highly resistant to digestion by human digestive enzymes; however, digestion of gluten by intestinal bacteria has recently been described.
by Paul Enck
A recent case-control study, led by Dr. Zhenjun Wu from the Department of Blood Transfusion and Clinical Laboratory at Qingdao University School of Medicine in Qingdao (China), has found that probiotics may combat SIBO in patients with gastrointestinal cancer and may alleviate some gastrointestinal symptoms.
by Andreu Prados
A recent study, led by Dr. Charles Mackay from the Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology at Monash University in Clayton (Australia), has found that the development of food allergies in mice could be linked to dietary elements including fibre and vitamin A.
by Kristina Campbell
The observed success of the low-FODMAP diet in reducing gastrointestinal (GI) symptoms in IBS made a group of researchers ask whether the diet could also address functional GI symptoms in those with inflammatory bowel diseases (IBDs) such as Crohn's disease. This idea was explored in a recent study from the group at Monash University (Australia) that originally developed and tested the low-FODMAP diet.
by Andreu Prados
A recent study, led by Dr. Wendy A. Henderson from the National Institute of Nursing Research at National Institutes of Health (NIH) in Bethesda (USA), and co-authored by Research Fellow Dr. Nicolaas Fourie, has found that the oral microbiota could be a useful source of information in patients with irritable bowel syndrome (IBS).
Inflammatory bowel disease (IBD) is a family of intestinal disorders including Crohn’s disease (CD) and ulcerative colitis (UC) that are characterized by chronic and recurring periods of severe colonic (UC) or intestinal (CD) inflammation and extraintestinal symptoms.
Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, affecting more than 10% of the population, with the highest impact in women. Although its origin is still unknown, reduced gut microbial diversity could be involved in its development.
